Skip to main content
OpenTrials
Completed

NCT Number: NCT00124020

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Pneumonia Bacterial Infections Bacterial Infections and Mycoses Infections Lung Diseases Pneumonia Pneumonia, Bacterial Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sheba Medical Center, Infectious Disease Unit

Tel Litwinsky, 52621, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.

Exclusion criteria

  • Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.

Treatment and study plan

Telavancin

Drug

Telavancin 10 mg/kg/day IV for up to 21 days

Other names: TD6424, VIBATIV

Vancomycin

Drug

Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days

Primary outcomes

  1. Clinical Response

    Time frame: 7-14 days following end of antibiotic treatment

    Clinical Response: Categorical (Cured, Failed or Indeterminate)

    • Failure - at least one of the following:
    • Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy
    • Termination of study med due to "lack of efficacy"
    • Death on or after Day 3 attributable to primary infection
    • Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
    • Indeterminate: Inability to determine outcome

Sponsors and collaborators

Lead sponsor

Cumberland Pharmaceuticals

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus

Acronym: ATTAIN2

Important dates

Study start
2005
Primary completion
2007
Study completion
2007
First posted
Jul 26, 2005
Registry last updated
Jan 16, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.